TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05822908: A Phase 1/2a, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered VO659 in Participants With Spinocerebellar Ataxia Ty

Sponsor: Vico Therapeutics B. V. · Phase: PHASE1/PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 68 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,741,350

Rescue Site Savings

+$4,465,050

Unlock Full NCT05822908 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05822908 Rescue Dossier →